SynAct Pharma to present at BioStock Investing in Life Science conference

By Public Technologies
  • SynAct Pharma will present at BioStock Investing in Life Science 2026 on Sept. 22 in Stockholm.
  • Management will attend LSX Congress USA 2026 in Boston on Sept. 22-24, including a panel session Sept. 22.
  • Investor and partnering meetings planned at European MidCap Event 2026 on Sept. 30-Oct. 1 in Paris.
  • Additional meetings set for Oct. 7-8 at Sachs Associates Biotech in Europe Forum in Basel.
  • Bio Japan in Yokohama scheduled for Oct. 7-8, with management available for partner discussions.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. SynAct Pharma AB published the original content used to generate this news brief on September 22, 2026, and is solely responsible for the information contained therein.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.